Skip to main content
Premium Trial:

Request an Annual Quote

Sophia Genetics Gains CE-IVD Mark for Leukemia Assay

CHICAGO (GenomeWeb) – Sophia Genetics said that it has received a CE-IVD mark for a molecular diagnostics test designed to improve detection of leukemia and other hematological diseases. The Swiss company called this the "world’s first capture-based myeloid clinical solution" to receive this designation from European regulators.

The test is a sequencing-based assay combined with data analytics to detect mutations that cause myeloid and lymphoid leukemia.

According to Lausanne, Switzerland-based Sophia, its technology helps improve genome reads and coverage uniformity, even in areas heavy in Gs and Cs. This, Sophia said, overcomes analytics limitations associated with biomarkers such as CEBPA, FLT3, and CALR.

Sophia Genetics said that its new myeloid test will support both biomarker-driven drug discovery and the personalization of cancer care.

Last week, the company announced that its Sophia AI machine learning platform now supports radiomics analysis. Sophia raised $30 million in a Series D round of venture capital last September.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.